Cargando…

遗传性球形红细胞增多症骨髓红系造血代偿特征

OBJECTIVE: To reveal the compensatory features of bone marrow(BM)erythropoiesis in hereditary spherocytosis(HS)and to explore the effect of diferent hemoglobin levels on this compensation. METHODS: Clinical and laboratory data of patients with HS were collected, and the peripheral blood absolute ret...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980641/
https://www.ncbi.nlm.nih.gov/pubmed/35381671
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.02.005
_version_ 1784681436352086016
collection PubMed
description OBJECTIVE: To reveal the compensatory features of bone marrow(BM)erythropoiesis in hereditary spherocytosis(HS)and to explore the effect of diferent hemoglobin levels on this compensation. METHODS: Clinical and laboratory data of patients with HS were collected, and the peripheral blood absolute reticulocytes counts value was taken as the surrogate parameter to evaluate the ability of erythropoiesis compensation. BM erythropoiesis compensation in HS with diferent degrees of anemia were evaluated. RESULTS: ①Three hundred and two patients were enrolled, including 115 with compensated hemolytic disease, 74 with mild anemia, 90 with moderate anemia, and 23 with severe anemia. ②Hemoglobin(HGB)was negatively correlated with serum erythropoietin in the decompensated hemolytic anemia group(EPO; rs=−0.585, P<0.001). ③The median absolute reticulocyte count(ARC)of HS patients was 0.34(0.27, 0.44)×10(12)/L, up to 4.25 times that of normal people. The maximum ARC was 0.81×10(12)/L, about 10 times that of normal people. The median ARC of patients with compensated hemolytic disease was 0.29(0.22, 0.38)×10(12)/L, up to 3.63 times that of normal people. The median ARC of patients with hemolytic anemia was 0.38(0.30, 0.46)×10(12)/L, which was significantly higher than the patients with compensated hemolytic disease, up to 4.75 times that of normal people(z=4.999, P=0.003). ④ ARC was negatively correlated with HGB in the compensated hemolytic disease group(rs=−0.177, P=0.002)and positively correlated with HGB in the decompensated hemolytic anemia group(rs=0.191, P=0.009). There was no significant difference in the ARC among patients with mild, moderate, and severe anemia(χ(2)=4.588, P=0.101). ⑤The median immature reticulocyte production index of the mild, moderate, and severe anemia groups was 13.1%(9.1%, 18.4%), 17.0%(13.4%, 20.8%), and 17.8%(14.6%, 21.8%), respectively; the mild anemia group had lower index values than the moderate and severe anemia groups(P(adj) values were both<0.05), but there was no significant difference between the latter groups(P(adj)=1.000). The median immature reticulocyte count of patients in the mild, moderate, and severe groups was 5.09(2.60, 7.74)×10(10)/L, 6.24(4.34, 8.83)×10(10)/L, and 7.00(3.07, 8.22)×10(10)/L, respectively; there was no significant difference among the groups(χ(2)=3.081, P=0.214). CONCLUSION: HGB can be maintained at a normal level through bone marrow erythropoiesis, while red blood cells are reduced in HS. However, once anemia develops, the bone marrow exerts its maximum erythropoiesis capacity and does not increase, regardless of anemia aggravation or serum EPO increase.
format Online
Article
Text
id pubmed-8980641
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-89806412022-04-13 遗传性球形红细胞增多症骨髓红系造血代偿特征 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To reveal the compensatory features of bone marrow(BM)erythropoiesis in hereditary spherocytosis(HS)and to explore the effect of diferent hemoglobin levels on this compensation. METHODS: Clinical and laboratory data of patients with HS were collected, and the peripheral blood absolute reticulocytes counts value was taken as the surrogate parameter to evaluate the ability of erythropoiesis compensation. BM erythropoiesis compensation in HS with diferent degrees of anemia were evaluated. RESULTS: ①Three hundred and two patients were enrolled, including 115 with compensated hemolytic disease, 74 with mild anemia, 90 with moderate anemia, and 23 with severe anemia. ②Hemoglobin(HGB)was negatively correlated with serum erythropoietin in the decompensated hemolytic anemia group(EPO; rs=−0.585, P<0.001). ③The median absolute reticulocyte count(ARC)of HS patients was 0.34(0.27, 0.44)×10(12)/L, up to 4.25 times that of normal people. The maximum ARC was 0.81×10(12)/L, about 10 times that of normal people. The median ARC of patients with compensated hemolytic disease was 0.29(0.22, 0.38)×10(12)/L, up to 3.63 times that of normal people. The median ARC of patients with hemolytic anemia was 0.38(0.30, 0.46)×10(12)/L, which was significantly higher than the patients with compensated hemolytic disease, up to 4.75 times that of normal people(z=4.999, P=0.003). ④ ARC was negatively correlated with HGB in the compensated hemolytic disease group(rs=−0.177, P=0.002)and positively correlated with HGB in the decompensated hemolytic anemia group(rs=0.191, P=0.009). There was no significant difference in the ARC among patients with mild, moderate, and severe anemia(χ(2)=4.588, P=0.101). ⑤The median immature reticulocyte production index of the mild, moderate, and severe anemia groups was 13.1%(9.1%, 18.4%), 17.0%(13.4%, 20.8%), and 17.8%(14.6%, 21.8%), respectively; the mild anemia group had lower index values than the moderate and severe anemia groups(P(adj) values were both<0.05), but there was no significant difference between the latter groups(P(adj)=1.000). The median immature reticulocyte count of patients in the mild, moderate, and severe groups was 5.09(2.60, 7.74)×10(10)/L, 6.24(4.34, 8.83)×10(10)/L, and 7.00(3.07, 8.22)×10(10)/L, respectively; there was no significant difference among the groups(χ(2)=3.081, P=0.214). CONCLUSION: HGB can be maintained at a normal level through bone marrow erythropoiesis, while red blood cells are reduced in HS. However, once anemia develops, the bone marrow exerts its maximum erythropoiesis capacity and does not increase, regardless of anemia aggravation or serum EPO increase. Editorial office of Chinese Journal of Hematology 2022-02 /pmc/articles/PMC8980641/ /pubmed/35381671 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.02.005 Text en 2022年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License.
spellingShingle 论著
遗传性球形红细胞增多症骨髓红系造血代偿特征
title 遗传性球形红细胞增多症骨髓红系造血代偿特征
title_full 遗传性球形红细胞增多症骨髓红系造血代偿特征
title_fullStr 遗传性球形红细胞增多症骨髓红系造血代偿特征
title_full_unstemmed 遗传性球形红细胞增多症骨髓红系造血代偿特征
title_short 遗传性球形红细胞增多症骨髓红系造血代偿特征
title_sort 遗传性球形红细胞增多症骨髓红系造血代偿特征
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980641/
https://www.ncbi.nlm.nih.gov/pubmed/35381671
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2022.02.005
work_keys_str_mv AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng
AT yíchuánxìngqiúxínghóngxìbāozēngduōzhènggǔsuǐhóngxìzàoxuèdàichángtèzhēng